Evaluation of the Effect of Autologous Fat and SVF Transplantation in Promoting Mechanical-stretch Induced in Vivo Skin Regeneration

April 18, 2016 updated by: Qing-FengLi Li,MD
The purpose of this study is to evaluating whether autologous grafted fat transplantation or SVF transplantation is safe and/or effective to accelerating skin regeneration and soft tissue expansion.

Study Overview

Detailed Description

Reconstruction of large scale skin defect is a challenge to clinical surgeons. Soft tissue expansion has won wide attention in recent years as it promotes skin regeneration with perfectly matched tissue. However, some patients with poor skin regenerative ability would suffer from skin flap over-thinned and even necrosis under the continuous stretching by silicone expander. This study is to evaluate the effects of autologous fat graft/SVF transplantation on accelerating skin regeneration and promoting tissue expansion process.

Patients aged between 18 to 60 years old who appear with deteriorated expanded skin will be enrolled and randomized into three groups, named as the experimental group and the control group. Patients from the FAT-GRAFT group will have a liposuction and subdermal fat graft transplantation. Patients from the SVF-TRANSPLANTATION group will have a liposuction and SVF will be separated and transplanted intradermally to expanded skin. Patients from the control group will have saline injection.

Study Type

Interventional

Enrollment (Anticipated)

60

Phase

  • Phase 2
  • Phase 1

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

  • Name: Qing-Feng Li, M.D., Ph.D.
  • Phone Number: 00862123271699

Study Locations

      • Shanghai, China
        • Recruiting
        • Shanghai Ninth People's Hospital
        • Contact:
          • Qing-Feng Li, M.D., Ph.D.
    • Shanghai
      • Shanghai, Shanghai, China, 200011
        • Recruiting
        • Shanghai Ninth People's Hospital, Affliated to Shanghai Jiao Tong University School of Medicine
        • Contact:
        • Contact:
        • Principal Investigator:
          • Qingfeng Li, MD, PhD
        • Sub-Investigator:
          • Shuangbai Zhou, MD
        • Sub-Investigator:
          • Yun Xie, MD, PhD

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 60 years (Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Inclusion Criteria:
  • Age of 18 to 60 years;
  • Expanding skin donor site at the face, neck, anterior chest wall, abdominal wall or back;
  • Implanted silicone expander of 80 to 600 ml in size;
  • History of deterioration in the expanded skin texture that did not improve after the inflation procedure was suspended for more than 2 weeks;
  • Persistent high level of expander internal pressure;
  • Need for further skin expansion;

Exclusion Criteria:

  • Not fit for soft tissue expansion treatment;
  • Evidence of infection, ischemia, ulcer or other pathological changes within the targeting area which defined as not suitable for expansion; or history of delayed healing, radiational therapy;
  • Significant renal, cardiovascular, hepatic and psychiatric diseases;
  • Significant medical diseases or infection (including but not limited to the carrier of hepatitis B virus or HIV)
  • BMI >30;
  • History of any hematological disease, including leukopenia , thrombocytopenia, or thrombocytosis;
  • History of allogenic bone marrow transplantation;
  • Long history of smoking;
  • Evidence of malignant diseases or unwillingness to participate.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: FAT-GRAFT
Fat graft transplantation
Liposuction will be performed and autologous fat graft will be harvest after washing with saline. Patients will receive autologous fat graft transplantation subdermally to expanded skin at the density of 0.1 ml/cm2.
Experimental: SVF-TRANSPLANTATION
Transplantation of resuspended SVF
Liposuction will be performed. SVF will be separated from autologous fat graft by collagenase digestion. Patients will receive resuspended SVF transplantation subdermally to expanded skin at the density of 1*10e6 cells/cm2.
Placebo Comparator: CONTROL
Same volume saline injection
Saline will be injected into expanded skin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Occurence of Major Adverse Events
Time Frame: Up to approximately 24 months after study start
Including expanded flap ischaemia, necrosis, fluidify, infection, and all other adverse events
Up to approximately 24 months after study start
To Measure the Change in Inflation Volume of the Silicone Expander from Baseline at 8 weeks
Time Frame: baseline and 8 weeks post treatment
Record the inflation volume of each expander with the maintained inner pressure.
baseline and 8 weeks post treatment

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
To Measure the Size of Expanded Flap with 3D laser scanner and calculate the surface of expanded skin
Time Frame: baseline and 8 weeks post treatment
Record the outface of expanded skin flap with 3D laser scanner and calculate the surface of expanded skin
baseline and 8 weeks post treatment
To Measure the Texture of Expanded Flap with VISIA scanner
Time Frame: 4 weeks and 8 weeks post treatment
Evaluate skin texture with VISIA scanner and compare the characteristics
4 weeks and 8 weeks post treatment
To Measure Expanded Skin Thickness by Ultrasound Scanning
Time Frame: baseline, 4 weeks and 8 weeks post treatment
Measure the dermal and epidermal thickness of expanded skin by ultrasound scanning
baseline, 4 weeks and 8 weeks post treatment

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

January 1, 2015

Primary Completion (Anticipated)

December 1, 2016

Study Registration Dates

First Submitted

December 26, 2014

First Submitted That Met QC Criteria

January 8, 2015

First Posted (Estimate)

January 13, 2015

Study Record Updates

Last Update Posted (Estimate)

April 20, 2016

Last Update Submitted That Met QC Criteria

April 18, 2016

Last Verified

April 1, 2016

More Information

Terms related to this study

Other Study ID Numbers

  • [2014]47

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Scar

Clinical Trials on FAT-GRAFT

3
Subscribe